ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1489

Promoting Smoking Cessation Among Rheumatoid Arthritis Patients: What Motivations and Barriers Are Reported after Being Offered a Smoking Cessation Intervention?

Lisa K. Stamp1, Megan Gath1, Pip Aimer1, Simon Stebbings2 and Gareth Treharne3, 1Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 2Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, 3Department of Psychology, University of Otago, Dunedin, New Zealand

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Educational innovation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Quality Measures and Quality of Care Poster Session (ARHP): Clinical Practice/Patient Care

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) may experience specific barriers
to smoking cessation but may also be motivated to quit to improve their health,
particularly if informed of the possible impact of smoking on disease activity,
treatment efficacy, and outcomes. Qualitative research on the perspectives of
smokers and ex-smokers with RA is needed to help design, implement, and
evaluate smoking cessation interventions that can be applied in clinical
practice if efficacious.

Methods: Semi-structured interviews were carried out with 29 ongoing smokers
and 10 ex-smokers with RA who had previously been invited to participate in a randomized
controlled trial of a novel RA-specific smoking cessation intervention (14/19
in the intervention group; 14/19 in the control group; 11/18 who had declined
being in the trial). The interviews were led by a researcher with no
involvement in the participants’ clinical care. Interview transcripts were
subjected to thematic analysis to investigate the motivations and barriers to
smoking cessation that are most pertinent to RA patients, which led us to
formulate themes outlining what we call ‘incentives’ and ‘drives’ to quit.

Results: Participants described five incentives to quit (health, arthritis,
social relationships, coping mechanism, and costs) and four drives to quit
(commitment, mental preparation, will power, and interventions). In particular,
participants highlighted how their health (in general and relating to their RA)
could provide an incentive to quit or be used as a rationalization for not
having quit. Living with RA contributed to the stress and negative emotions
experienced by participants and also limited the availability of coping methods
that might be used in places of smoking, particularly those coping methods requiring
mobility. None of the 10 participants who had quit smoking mentioned having
previously relied on smoking as a coping method.

Conclusion: When RA patients have been informed that continued smoking may
impact on the outcomes of their RA it can provide an important incentive to
quit smoking that may bolster other general incentives to quit. At the same
time, RA patients experience stress and mobility difficulties that often make
it difficult to quit smoking despite knowing the general and RA-specific health
benefits. Overall, the incentives and drives revealed in this research also
indicate ways that RA patients might be supported in developing the motivation
to quit smoking and ways of overcoming barriers. RA patients who report using
smoking to cope may benefit from psychological interventions to help them
replace or reframe that coping method and bolster other psychological processes
that can drive smoking cessation.

 


Disclosure: L. K. Stamp, None; M. Gath, None; P. Aimer, None; S. Stebbings, None; G. Treharne, None.

To cite this abstract in AMA style:

Stamp LK, Gath M, Aimer P, Stebbings S, Treharne G. Promoting Smoking Cessation Among Rheumatoid Arthritis Patients: What Motivations and Barriers Are Reported after Being Offered a Smoking Cessation Intervention? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/promoting-smoking-cessation-among-rheumatoid-arthritis-patients-what-motivations-and-barriers-are-reported-after-being-offered-a-smoking-cessation-intervention/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/promoting-smoking-cessation-among-rheumatoid-arthritis-patients-what-motivations-and-barriers-are-reported-after-being-offered-a-smoking-cessation-intervention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology